Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACI-91 placebo-controlled phase 2 study in mild to moderate Alzheimer's disease
2008-005260-14Phase 2Completed
- Sponsor
- AC Immune SA
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ACI-91 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Sep 2008; status: completed.
02
Drugs
pirenzepine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-005260-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005260-14.